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Yueh-Te Lin1, Jhih-Sian Chen2, Ming-Heng Wu3, I-Shan Hsieh2, Chen-Hsien Liang1, Cheng-Lung Hsu4,
Tse-Ming Hong1,5 and Yuh-Ling Chen1,2
Myofibroblasts have a key role in wound healing by secreting growth factors and chemoattractants to create
new substrates and proteins in the extracellular matrix. We have found that galectin-1, a b-galactose-binding
lectin involved in many physiological functions, induces myofibroblast activation; however, the mechanism
remains unclear. Here, we reveal that galectin-1-null (Lgals1 / ) mice exhibited a delayed cutaneous wound
healing response. Galectin-1 induced myofibroblast activation, migration, and proliferation by triggering
intracellular reactive oxygen species (ROS) production. A ROS-producing protein, NADPH oxidase 4 (NOX4),
was upregulated by galectin-1 through the neuropilin-1/Smad3 signaling pathway in myofibroblasts. Subcuta-
neous injection of galectin-1 into wound areas accelerated the healing of general and pathological (strepto-
zotocin-induced diabetes mellitus) wounds and decreased the mortality of diabetic mice with skin wounds.
These findings indicate that galectin-1 is a key regulator of wound repair that has therapeutic potential for
pathological or imperfect wound healing.
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INTRODUCTION
Wound healing is a complicated physiological process that
includes hemostasis, inflammation, proliferation, and a remo-
deling phase (Singer and Clark, 1999; Diegelmann and Evans,
2004; Velnar et al., 2009). Numerous cell signaling events
are required for one or more phases and regulate this highly
controlled repair process (Diegelmann and Evans, 2004; Clark
et al., 2007). In pathologic conditions such as diabetes
mellitus, ischemia and increased pressure can result in
chronic and nonhealing wounds (Guo and Dipietro, 2010).
Approximately 3 million people in the United States and 2%
of the population of industrialized countries suffer
from nonhealing wounds every year (Menke et al., 2007;
Welt et al., 2009). Furthermore, the number of patients with
chronic wound healing is expected to increase because of the
increase in the elderly population over the next 20 years.
Therefore, a greater understanding of the disease pathology
and identification of rapid and effective therapies for impaired
wound healing are urgently needed.
During wound healing, fibroblasts are activated to become
myofibroblasts that migrate to wound areas. Myofibroblasts
have key roles in wound healing, including growth factor
secretion, extracellular matrix synthesis, and angiogenesis
(Tomasek et al., 2002; Sarrazy et al., 2011). In nonhealing
and chronic wounds, fibroblasts display cellular characteri-
stics of premature senescence (Harding et al., 2005; Clark,
2008), increased apoptosis (Graves et al., 2006), disturbed
proliferation (Loots et al., 1999), and little response to stimula-
tion (Lerman et al., 2003). Recent studies have suggested that
targeting myofibroblast differentiation may offer a promising
therapeutic strategy for the treatment of improper or impaired
wound healing (Sampson et al., 2012; Lai et al., 2013).
Galectin-1 is a prototypic member of the galectin family
that binds b-galactoside and is differentially expressed by
various normal and pathological tissues. Galectin-1 regulates
a wide range of biological functions such as cell growth,
cell adhesion, metastasis, angiogenesis, neuron development,
cardiovascular disease, and immunomodulation (Thijssen
et al., 2006; Salatino et al., 2008; Wu et al., 2009;
Sakaguchi et al., 2011; Smetana et al., 2013; Al-Salam and
Hashmi, 2014). Previous studies have indicated that galectin-1
ORIGINAL ARTICLE
1Institute of Basic Medical Sciences, College of Medicine, National Cheng
Kung University, Tainan, Taiwan; 2Institute of Oral Medicine, College of
Medicine, National Cheng Kung University, Tainan, Taiwan; 3Institute for
Translational Medicine, Taipei Medical University, Taipei, Taiwan;
4Department of Internal Medicine, Division of Hematology and Oncology,
Chang Gung Memorial Hospital, Taoyuan, Taiwan and 5Graduate Institute of
Clinical Medicine, College of Medicine, National Cheng Kung University,
Tainan, Taiwan
Correspondence: Yuh-Ling Chen or Tse-Ming Hong, Institute of Oral Medicine,
College of Medicine, National Cheng Kung University, No. 1 University Road,
Tainan, 70101, Taiwan.
E-mail: yuhling@mail.ncku.edu.tw or tmhong@mail.ncku.edu.tw
Received 12 March 2014; revised 20 May 2014; accepted 4 June 2014;
accepted article preview online 9 July 2014; published online 14 August
2014
Abbreviations: HGF, human gingival fibroblast; H2O2, hydrogen peroxide;
NOX4, NADPH oxidase 4; NRP1, neuropilin-1; O2
 , superoxide; PDGF,
platelet-derived growth factor; ROS, reactive oxygen species; TGF-b,
transforming growth factor-b; a-SMA, a-smooth muscle actin; WT, wild type
258 Journal of Investigative Dermatology (2015), Volume 135 & 2015 The Society for Investigative Dermatology
is enriched in cancer-associated fibroblasts and promotes
growth and invasion of adjacent cancer cells (Wu et al.,
2011; Xue et al., 2011). Galectin-1 has been associated with
myofibroblast differentiation in murine dermal fibroblasts, and
treatment with galectin-1 was found to promote myofibroblast
activation (Goldring et al., 2002). Cytokine production and
proliferation in pancreatic stellate cells or transdifferentiation
of hepatic stellate cells are induced by high expression of
galectin-1 (Maeda et al., 2003; Maeda et al., 2004; Masamune
et al., 2006). Moreover, galectins have been reported to be
regulated during wound healing in vitro and in vivo (Klı´ma
et al., 2009; Dvorˇa´nkova´ et al., 2011; Ga´l et al., 2011).
Although galectin-1 is an important mediator of myo-
fibroblast activation, the mechanism and regulation of
galectin-1-mediated myofibroblast activation and wound
healing are still unclear. Therefore, we hypothesized that
galectin-1 participates in wound healing by inducing
myofibroblast activation. In this study, we used galectin-1
knockout (Lgals1 / ) mice to examine the role of galectin-1
in cutaneous wound healing and address the molecular mech-
anism underlying galectin-1-induced fibroblast activation. The
potential therapeutic effect of galectin-1 on physiological and
pathological wound healing was also evaluated.
RESULTS
Lgals1 / mice have delayed cutaneous wound healing
compared with wild-type mice
To test our hypothesis that galectin-1 is involved in the
regulation of wound healing in vivo, we used a skin wound
healing model and Lgals1 / mice to examine the effect of
galectin-1 on skin wound healing. After dermal excision,
wound areas were measured every other day for 8 days. We
found that Lgals1 / mice had bloody wounds and poor
scar formation, and they exhibited signs of inflammation at
day 2 and delayed wound closure at day 5 (Figure 1a). By day
7, B90% of the wound was closed in wild-type (WT) mice,
compared with 50% in Lgals1 / mice (Supplementary
Figure S1a online). Quantification of the wound area by
ImageJ software (National Institutes of Health, Bethesda,
MD) for 8 consecutive days showed that the rate of wound
healing was significantly decreased in Lgals1 / mice rela-
tive to WT mice (Figure 1b). Reepithelization and collagen
deposition in Lgals1 / mouse wounds measured by hema-
toxylin and eosin and Masson’s trichrome staining were also
less than those in WT mice (Figure 1c and Supplementary
Figure S1b online), especially in Lgals1 / mouse 3.
However, the sublayers of the skin exhibited no significant
differences between WT and Lgals1 / mice (Supplementary
Figure S1c online).
Collectively, these data suggest that Lgals1 / mice have
poor wound healing ability compared with WT mice. Total
protein from the skin and wound areas of the mice was
collected to detect the expression of galectin-1, a-smooth
muscle actin (a-SMA), and fibronectin by western blotting. In
WT mice, galectin-1 was upregulated in the wound areas
(W1–W3) compared with normal skin (N1–N3), and expres-
sion of a-SMA (a major myofibroblast activation marker,
Darby et al., 1990) and fibronectin was also increased
(Figure 1d). The a-SMA level in the wound areas was
noticeably lower in Lgals1 / mice than in WT mice.
Immunohistochemistry revealed that more myofibroblasts
were migrating toward the wound areas in WT mice than in
Lgals1 / mice at day 3 (Supplementary Figure S1d online).
This result suggests that galectin-1 facilitates myofibroblast
activation and wound healing in vivo.
Galectin-1 has a pleiotropic role in myofibroblast activation
To examine the functional role of galectin-1 in fibroblasts, we
treated human gingival fibroblasts (HGFs) with active and
heat-inactivated galectin-1. Treatment of HGFs with active
galectin-1 increased the expression of a-SMA relative to
treatment with denatured galectin-1 (Figure 2a). Consistently,
knockdown of galectin-1 by short hairpin RNA (shGal-1) in
activated fibroblasts, cancer-associated fibroblasts, and skin
myofibroblasts (CCD966-SKs) was accompanied by decreased
expression of a-SMA, fibronectin, and collagen IA (Figure 2b
and c). The migration and proliferation of myofibroblasts were
significantly suppressed in shGal-1-myofibroblasts (Figure 2d
and e). Taken together, these results suggest that galectin-1 has
a key role in myofibroblast activation.
Galectin-1 induces ROS production in myofibroblasts and an
animal model
Several studies have indicated that reactive oxygen species
(ROS) generation is a key step during myofibroblast activation
(Cucoranu et al., 2005; Amara et al., 2010; Bondi et al., 2010;
Sampson et al., 2011). In light of previous findings that
galectin-1 induced ROS generation in neutrophils (Almkvist
et al., 2002), we were interested in determining whether
ROS would be generated in myofibroblasts treated with
galectin-1. First, we detected superoxide (O2
 ) and
hydrogen peroxide (H2O2) levels in several types of fibro-
blasts using lucigenin and 2’,7’-dichlorodihydrofluorescein
diacetate, respectively. We found that O2
 and H2O2 levels
in myofibroblasts were tightly associated with galectin-1
expression (Figure 3a and Supplementary Figure S2a and b
online). ROS have been reported to induce corneal wound
healing in vivo (Huo et al., 2009) and provide detoxification
for wound healing (auf dem Keller et al., 2006). We therefore
also measured the ROS levels in normal skin and wounds in
WT and Lgals1 / mice. We found that Lgals1 / mice had
lower ROS generation in normal skin and wounds compared
with WT mice (Figure 3b). Importantly, in the presence of the
ROS scavenger N-acetyl-L-cysteine, a-SMA expression and
the proliferation and migration of myofibroblasts decreased in
a concentration-dependent manner (Figure 3c–e). Moreover,
treatment of H2O2 (0–60mmol l
 1) for 2 days dose-depen-
dently stimulated cell proliferation of shGal-1-myofibroblasts
(Supplementary Figure S2c online). These results indicate that
ROS generation is essential for galectin-1-induced myofibro-
blast activation.
Galectin-1 induces ROS generation in myofibroblasts by
regulating NOX4
Several studies have indicated that the NAD(P)H oxidase
family has an important role in ROS production in various
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cell types (Cucoranu et al., 2005; Bedard and Krause, 2007;
Hecker et al., 2009). In fibroblasts, NADPH oxidase 4 (NOX4)
is a major ROS-generating protein and regulates cell
hemostasis. Therefore, we hypothesized that galectin-1
induces ROS production in fibroblasts by regulating the
expression of NOX4. We found that expression of NOX4
and NADPH oxidase activity were significantly decreased in
Gal-1-silenced oral and skin myofibroblasts (Figure 4a and
Supplementary Figures S2d and S3 online). Moreover, we
found that silencing of NOX4 using NOX4-specific short
hairpin RNA apparently decreased the expression of a-SMA
in myofibroblasts (Figure 4b). Suppression of endogenous
NOX4 also resulted in a decrease in O2
 and H2O2 genera-
tion (Supplementary Figure S2e and f online). Furthermore, we
found that NOX4 knockdown effectively inhibited the pro-
liferation and migration of oral and skin myofibroblasts
(Figure 4c and d). Immunofluorescence analysis revealed that
galectin-1, NOX4, and a-SMA colocalized at the site of injury
and fewer myofibroblasts were present in Lgals1 / mice
(Figure 4e and Supplementary Figure S4 online). Collectively,
these results indicate that NOX4 mediates galectin-1-induced
ROS production and myofibroblast activation.
Galectin-1 induces myofibroblast activation through neuropilin-1
binding and the Smad3/NOX4 pathway
We next investigated the possible mechanism of galectin-1-
induced NOX4 expression. Our previous studies showed that
galectin-1 can bind neuropilin-1 (NRP1) on vascular endothe-
lial cells to regulate angiogenesis (Hsieh et al., 2008). Recent
studies have indicated that NRP1 promotes myofibroblast
activation by enhancing Smad pathway signaling in a variety
of physiological and disease conditions (Cao et al., 2010a, b).
Hence, we first examined whether galectin-1 binds NRP1 on
fibroblasts and induces Smad3 phosphorylation. In a flow
cytometric analysis, FITC-conjugated galectin-1-binding HGFs
were abolished by silencing of NRP1 (Figure 5a), indicating
that NRP1 is a major binding site for galectin-1 in fibroblasts.
HGFs treated with galectin-1 exhibited an increase in Smad3
phosphorylation (Ser423/425) (Supplementary Figure S5a
online). Furthermore, knockdown of NRP1 in myofibroblasts
suppressed Smad3 activation, NOX4 expression, ROS produc-
tion, and concomitant myofibroblast activation (Figure 5b and
c, and Supplementary Figure S5b online).
Treatment with lactose, a galactoside competitor for
galectin-1 binding, attenuated Smad3/NOX4/a-SMA pathway
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Figure 1. Lgals1 / mice have delayed wound healing compared with wild-type (WT) mice. (a) Representative macroscopic images of wounds in WT and
Lgals1 / mice at 2 and 5 days after wounding show delayed healing in Lgals1 / wounds. (b) The areas of the wounds were quantified by ImageJ (NIH) over
multiple time points (four wounds/mouse, n¼ 10–15 mice per group). Values represent the mean±SD. **Pp0.01. (c) Representative hematoxylin and eosin and
Masson’s trichrome staining in the WT and Lgals1 / wounds at day 8. Arrowheads indicate wound margins. Scale bars¼200mm. (d) Western blotting of
galectin-1, a-smooth muscle actin (a-SMA), and fibronectin in three randomly chosen excisional wounds (W1–W3) and normal skin (N1–N3) from WT and
Lgals1 / mice. b-Actin was used as a loading control.
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signaling and activation of oral and skin myofibroblasts
(Supplementary Figure S5c online). The Smad3/NOX4 path-
way is known to mediate transforming growth factor-b1 (TGF-
b1)-induced myofibroblast activation, but the relationship
between Smad3 and NOX4 is still controversial (Cucoranu
et al., 2005; Hecker et al., 2009). To investigate this
relationship, HGFs were treated with SIS3, a specific phos-
phorylation inhibitor for Smad3, for 24 hours and then treated
with galectin-1 before analysis of NOX4 and a-SMA
expression. Inhibition of Smad3 effectively blocked galectin-
1-induced NOX4 and a-SMA expression in fibroblast and
myofibroblasts (Figure 5d and e), whereas phosphorylation of
Smad3 was not affected in NOX4-depleted myofibroblasts
(Supplementary Figure S5d online), indicating that NOX4
expression occurs downstream of Smad3. Previous studies
have shown that NRP1 interacts with TGF-b1 during
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Figure 2. Galectin-1 promotes fibroblast activation, migration, and proliferation. (a) Western blotting of a-smooth muscle actin (a-SMA) in human gingival
fibroblasts (HGFs) treated with various concentrations of active or heat-denatured galectin-1 for 24 hours. (b) Western blotting of a-SMA and Gal-1 in
myofibroblasts. (c) The mRNA expression of a-SMA, fibronectin, and collagen IA in shGal-1-cells was compared with control cells (shLuc-cells, small hairpin RNA
for luciferase). (d) A wound healing migration assay was described in the Materials and Methods. Full lines indicate the initial wound area and dotted lines indicate
the migrating front of cells. Arrows indicate the cellular bridges. Scale bars¼ 200mm. (e) Cell proliferation of shGal-1 and shLuc myofibroblasts was detected.
Results are expressed as mean±SEM, n¼ 4. *Pp0.05; **Pp0.01; ***Pp0.001.
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myofibroblast activation. To test the possibility that galectin-1-
induced Smad3 activation occurs through increased TGF-b
signaling, HGFs were pretreated with SB-431542, an inhibitor
of the type-I TGF-b receptor. No difference was observed
upon treatment with SB-431542 (Supplementary Figure S5e
online), suggesting that TGF-b signaling is not required for
galectin-1-induced Smad3 phosphorylation.
Smad3/NOX4-mediated, galectin-1-induced wound healing
was then demonstrated in vivo. Upregulation of galectin-1
was accompanied by increases in the levels of p-Smad3, total
Smad3, and NOX4 in wounded tissues of WT mice (Figure 5f
and Supplementary Figure S6 online), whereas only total
Smad3 was upregulated in the wound tissues of Lgals1 /
mice. The expression levels of NRP1 and TGF-b1 in the
wounds of WT and Lgals1 / mice were not significantly
different (Supplementary Figure S5f online). Smad3/
NOX4-mediated, galectin-1-induced fibroblast activation
was also demonstrated in murine dermal myofibroblasts
(Figure 5g). Taken together, these results indicate that NRP1
acts as a receptor for galectin-1 in fibroblasts and mediates
galectin-1-induced fibroblast activation during wound
healing.
Galectin-1 accelerates normal and diabetic wound healing in
animal models
We showed that galectin-1 induces signaling via the Smad3/
NOX4 pathway and promotes ROS generation and that
Lgals1 / mice present delayed wound healing. Therefore,
we evaluated whether topical administration of galectin-1
could augment wound closure in an animal model. Paired,
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6-mm dorsal full-thickness excisional wounds were created in
mice. At 3 days after the wounds were established, we
topically injected 100mg of recombinant human galectin-1
underneath the scar and measured the wound healing
area. We found that wounds exposed to galectin-1 healed
more rapidly than those treated with the control solution
(Figure 6a and b).
To further investigate the effect of galectin-1 treatment on
impaired wound healing, streptozotocin-induced diabetes
mellitus mice were established (Rossini et al., 1977). After 2
weeks, the blood glucose levels of these mice were all higher
than 400 mg dl 1 (Supplementary Table S1 online). Wounds
were generated by 6-mm dermal biopsy punches, and
galectin-1 (80–100mg per wound) was injected underneath
the scar for 7 consecutive days. Wound healing was measured
for 12 consecutive days. We found that wounds treated with
galectin-1 healed significantly faster than those treated with
phosphate-buffered saline after day 3 and severe illness and
death were prevented in mice (Figure 6c and d, and
Supplementary Figure S7a online). The body weight of control
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mice was significantly decreased at day 8 (Supplementary
Figure S7b online). In contrast, galectin-1-treated mice healed
faster and survived well until 2 months, even though they still
presented high blood glucose levels (Supplementary Figure
S7c online). This observation suggests that galectin-1 not only
reverses impaired wound healing in diabetic mice but also
prevents severe illness and death. Therefore, galectin-1 treat-
ment could be a potential therapy for impaired wound healing.
DISCUSSION
Elucidation of complex wound healing pathways is important
for identifying therapeutic targets for clinical treatment. In this
study, we showed that galectin-1 has an important role in
myofibroblast activation and wound healing (Figure 6e).
Murine skin wound healing experiments confirmed that
reduced myofibroblast recruitment to wound sites in
Lgals1 / mice resulted in delayed wound healing. We also
demonstrated that galectin-1 binds to NRP1 on myofibroblasts
to activate Smad3 signaling and increase NOX4 expression
and ROS production. Furthermore, topical administration of
galectin-1 effectively augmented wound closure in normal
and diabetic dermal excisional wound models. Evidence from
this study strongly suggests that targeting of the galectin-1/
NRP1/Smad3 pathway may be important for clinical therapy
of general, severe, and disease (diabetes mellitus)-induced
impaired wound healing.
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and reactive oxygen species (ROS) production. (d, e) The effect of SIS3 on the expression of p-Smad3, t-Smad3, NOX4, and a-SMA in fibroblasts. (f, g) Western
blotting analysis on the galectin-1/Smad3/NOX4 pathway in mouse wounds and murine dermal myofibroblasts (MDAFs). Results are expressed as mean±SD,
n¼ 3. **Pp0.01.
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Figure 6. Topical administration of galectin-1 accelerates wound healing in animal models. (a) Representative macroscopic images of wounds in phosphate-
buffered saline (PBS)- or galectin-1-treated healthy mice at 0, 4, and 5 days after wound show accelerated healing in galectin-1-treated wounds. (b) The area of the
wounds was quantified by ImageJ software over multiple time points. (c, d) Images of wounds in PBS- or galectin-1-treated streptozotocin (STZ)-induced diabetes
mellitus (DM) mice. Wound area was measured at the indicated time points and quantified by ImageJ analysis. (e) Diagram shows a working model of how
galectin-1 promotes wound healing in mice with excisional wound through regulation of neuropilin-1 (NRP1)/Smad3/NADPH oxidase 4 (NOX4) signaling to
modulate reactive oxygen species (ROS) production in myofibroblasts. Results are expressed as mean±SD. **Pp0.01; ***Pp0.001.
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Galectin-1 is well known to be involved in development,
differentiation, morphogenesis, tumor metastasis, and immune
regulatory function (Smetana et al., 2013). In this study, we
demonstrated for the first time that galectin-1 can promote
wound healing by inducing Smad3/NOX4 signaling to
increase ROS production in myofibroblasts. However, the
healing process is complicated, and different cells are
involved in different phases; thus, galectin-1-mediated
regulation of different cell types and healing phases during
wound repair remains unclear. Recent immunohistochemical
observations showed that the regulation of galectins during
wound healing in rat skin and trachea is dynamic; galectin-1 is
upregulated during the early phases of healing, and then
galectin-3 is slightly upregulated during the later phases
(Maeda et al., 2004; Grendel et al., 2012). In addition to its
expression in myofibroblasts, galectin-1 is expressed in skin
keratinocytes and mediates cell matrix interactions, suggesting
a potential role in reepithelialization during wound healing
(Chen et al., 2012). However, a previous study showed that
both endogenous galectin-1 and exogenously added galectin-
1 did not affect the reepithelialization rate of corneal wounds
(Cao et al., 2002). In Lgals1 / mice, galectin-1 has been
demonstrated to have essential roles in the control of
inflammation and neovascularization (Thijssen et al., 2006;
Seropian et al., 2013). The effects of galectin-1 in other cell
types, such as macrophages, neutrophils, and endothelial
cells, during different healing phases should be studied further.
ROS have pivotal roles in physiological and pathological
processes, including the progression of wound healing (auf dem
Keller et al., 2006; Bedard and Krause, 2007; Huo et al., 2009;
Bryan et al., 2012). During wound healing, ROS production in
constructive and destructive cells is associated with a fine
balance in the remodeling of tissue. ROS are thought to act as
cellular messengers to stimulate key processes associated with
wound healing, including cell motility, cytokine activity, and
angiogenesis. Here, we report that increased ROS production is
required for galectin-1-regulated myofibroblast activation. The
levels of ROS in skin wound areas in Lgals1 / mice were
significantly lower than those in WT mice, suggesting that ROS
are involved in the effects of galectin-1 on wound repair.
Maintaining the balance between oxidants and antioxidants is
crucial for proper wound healing. Several investigators have
studied the effects of growth factors (e.g., epidermal growth
factor and TGF-b) on oxidative events during wound healing
(Huo et al., 2009; Bondi et al., 2010). Recently, platelet-derived
growth factor (PDGF)-BB, an active ingredient of the FDA (Food
and Drug Administration)-approved wound treatment gel
becaplermin that accelerates wound closure of chronic
diabetic ulcers, was shown to significantly increase ROS
levels in the early phase of wound healing, followed by a
decrease in the late phase, suggesting that PDGF administration
may modulate reactive oxidation depending on the stage of the
wound healing process (Kaltalioglu et al., 2013). Further studies
are necessary to characterize the effects of exogenous galectin-
1 administration or endogenous galectin-1 expression on
reactive oxidation over the course of cutaneous wound
healing, particularly to determine whether galectin-1 protects
the oxidative balance.
NRP1 is a co-receptor for several growth factors and has
multiple functions involved in development, immunity, and
cancer. Although NRP1 was initially shown to bind sema-
phorin 3A and vascular endothelial growth factor to regulate
axonal guidance and angiogenesis, recent findings have
revealed that it has a much broader spectrum of activity. In
particular, NRP1 binds TGF-b1, hepatocyte growth factor, and
PDGF and their receptors (Prud’homme and Glinka, 2012).
These ligands and pathways are all relevant to wound healing.
Our previous study showed that NRP1 is a receptor for
galectin-1 in vascular endothelial cells that promotes
galectin-1-induced vascular endothelial growth factor
receptor-2 signaling and endothelial migration (Hsieh et al.,
2008). In this study, we demonstrated that NRP1 is a
predominant binding protein for galectin-1 in myofibroblasts
and mediates galectin-1-induced myofibroblast activation.
Depletion of NRP1 in myofibroblasts blocks galectin-1
binding and the regulation of Smad3/NOX4. An NRP1-
neutralizing antibody was shown to ameliorate the
recruitment of activated hepatic stellate cells that exhibit the
highly motile myofibroblast phenotype, thereby blocking rat
liver fibrosis induced by liver injury (Cao et al., 2010a). Cao
et al. (2010b) reported that elimination of NRP1 in fibroblasts
decreased Smad2/3 phosphorylation and a-SMA expression
and also arrested cell growth. These studies indicate that NRP1
might be a key mediator in maintaining tissue homeostasis.
Our results show that pretreatment with an inhibitor of the
TGF-b1 receptor does not influence galectin-1-induced Smad3
activation or NOX4/ROS production. The levels of TGF-b1 in
wounds were not different between WT and Lgals1 / mice,
but Lgals1 / mice presented delayed wound repair, suggest-
ing that augmentation of wound healing by galectin-1 is
independent of TGF-b signaling. Conversely, we did not
observe a change in galectin-1 expression upon TGF-b1
treatment (Wu et al., 2011) that excludes the possibility that
galectin-1 is the downstream mediator of TGF-b1-induced
myofibroblast transdifferentiation. NRP1 has been shown to
colocalize with PDGF-receptor b in hepatic stellate cells and
increase PDGF binding to PDGF receptor b to promote
downstream signaling and hepatic stellate cell activation
(Cao et al., 2010a). NOX4 is also critical for modulation of
the pulmonary myofibroblast response to PDGF (Amara et al.,
2010). PDGF-induced myofibroblast transdifferentiation is
associated with upregulation of galectin-1 (Fitzner et al.,
2005). Therefore, binding of galectin-1 to the NRP1/PDGFR
receptor complex and its interaction with PDGF to regulate
wound healing deserve further investigation.
In summary, our study demonstrated the important role and
mechanism of action of galectin-1 in the course of wound
healing in vitro and in vivo. Tuning of the galectin-1/NRP1/
Smad3 signaling pathway may provide a therapeutic option
for impaired wound healing. Consequently, analysis of clinical
specimens based on this concept is warranted.
MATERIALS AND METHODS
Mice and cutaneous wound model
Lgals1 / mice were originally produced and deposited in the
Mutant Mouse Regional Resource Center by the Consortium for
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Functional Glycomics supported by the National Institute of General
Medical Sciences (GM62116, Poirier and Robertson, 1993) and were
maintained in the National Cheng Kung University laboratory animal
center. The animals were raised and cared for according to the
guidelines of the National Science Council, Taiwan. The mouse
experiments were approved by the institutional animal care and use
committee. For further information, see Supplementary Materials and
Methods online.
Isolation and culture of fibroblasts
Cancer-associated fibroblasts and HGFs were isolated from oral
cancer tissues and normal human gingival tissues as previously
described (Wu et al., 2011). For further information, see
Supplementary Materials and Methods online.
Quantitative real-time PCR
Primer sequences and other experiment details are reported in
Supplementary Materials and Methods online.
Histochemical studies and immunohistochemistry
Serial 5-mm-thick histological sections were stained with hematoxylin
and eosin or Masson’s trichrome. Other details are reported in
Supplementary Materials and Methods online.
Quantification of superoxide and hydrogen peroxide
Lucigenin-enhanced chemiluminescence and 2’,7’-dichlorodihydro-
fluorescein diacetate were used to measure O2
 and H2O2, respec-
tively. For further information, see Supplementary Materials and
Methods online.
Statistical analysis
The experiments were assessed using unpaired Student’s t-test or one-
way analysis of variance. The values represent the mean±SEM or SD.
Prism 5 software (USA) was used for statistical analysis.
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